Haemonetics Schedules Q3 Webcast Emphasizing Hospital and Plasma Collection Technologies

Haemonetics readies Q3 results discussion, underlines clinical and plasma collection focus

Main Topic — Emphasis on hospital and plasma collection technologies

Haemonetics is making its third-quarter fiscal 2026 financial results available and schedules a management call to discuss operational performance and product priorities, underscoring its focus on hospital technologies and plasma collection systems. The company highlights that the upcoming investor webcast will reference both the earnings release and a supplemental presentation that outline business trends and product deployment across hospitals, plasma centers and blood banks.

Management is positioning the call to address how Haemonetics’ end-to-end plasma collection technologies and hospital-focused products are advancing standards of care and operational efficiency in customer facilities. The company signals ongoing emphasis on technologies that optimize plasma center throughput and enable blood centers to collect in-demand components, indicating these product areas remain central to its commercial strategy and customer outreach.

During the event Haemonetics plans to respond to analyst and customer-focused questions about adoption, service and operational support for its suite of solutions, reflecting the company’s continuing engagement with health-care providers to improve quality, effectiveness and efficiency of care delivery. The webcast provides a forum to discuss integration of devices and services that target transfusion safety and plasma supply chain optimization.

Webcast and documentation logistics

Haemonetics hosts the live conference call and webcast at 8:00 a.m. ET on Feb. 5, 2026, and advises participants to register in advance to receive dial-in details and a personalized PIN, though registration is optional. The live webcast link is available on the company’s Investor Relations website; a replay goes live at 11:00 a.m. ET on Feb. 5 and remains accessible for one year through the same link.

Corporate contacts and company profile

Haemonetics posts the Third Quarter Fiscal 2026 Earnings Release and Supplemental Earnings Presentation on its Investor Relations site and provides investor contacts Olga Guyette (VP—Investor Relations & Treasury) and David Trenk (Manager—Investor Relations) with phone numbers for inquiries, and media contact Josh Gitelson (Sr. Director—Global Communications) for press matters. The company identifies itself as a global medical technology firm focused on hospital technologies, end-to-end plasma collection systems and products for blood centers; further information and contact emails are available on www.haemonetics.com.